Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes adverse events  compared with placebo (very low certainty).
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes change from baseline in FVC (% predicted) compared with placebo (very low certainty).
It is very uncertain whether short‐acting inhaled beta‐2 agonists changes sputum volume (mL) compared with placebo (very low certainty).
It is very uncertain whether short‐acting inhaled muscarinic antagonists changes change from baseline in FEV1 (% predicted) compared with placebo (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether probiotics changes occurrence of HAEC compared with placebo (very low certainty).
Probiotics showed no clear difference in severity of HAEC Â compared with placebo (low certainty).
Probiotics showed no clear difference in recurrent episodes of HAEC compared with placebo (low certainty).
Antibiotics showed no clear difference in failure to induce clinical remission at end of study compared with placebo (high certainty).
Antibiotics showed no clear difference in failure to induce clinical response at end of study compared with placebo (low certainty).
Antibiotics showed no clear difference in serious adverse events compared with placebo (low certainty).
Antibiotics showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
It is very uncertain whether antibiotics plus probiotics changes failure to induce clinical remission at end of study compared with placebo or no intervention (very low certainty).
The review found no eligible studies for this question.
It is very uncertain whether antibiotics plus probiotics changes serious adverse events compared with placebo or no intervention (very low certainty).
It is very uncertain whether antibiotics plus probiotics changes withdrawals due to adverse events compared with placebo or no intervention (very low certainty).
Certolizumab pegol probably leads to lower failure to maintain clinical remission at week 26(1 RCT, 428… compared with placebo (moderate certainty).